Tailoring recombinant protein quality by rational media design
The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Clinical efficacy and safety of recombinant proteins are closely associated with their structural characteristics. The major quality attributes comprise glycosylation, charge variants (oxidation, deamidation, and C‐ & N‐terminal modifications), aggregates, low‐molecular‐weight species (LMW), and misincorporation of amino acids in the protein backbone. Cell culture media design has a great potential to modulate these quality attributes due to the vital role of medium in mammalian cell culture. The purpose of this review is to provide an overview of the way both classical cell culture medium components and novel supplements affect the quality attributes of recombinant therapeutic proteins expressed in mammalian hosts, allowing rational and high‐throughput optimization of mammalian cell culture media. A selection of specific and/or potent inhibitors and activators of oligosaccharide processing as well as components affecting multiple quality attributes are presented. Extensive research efforts in this field show the feasibility of quality engineering through media design, allowing to significantly modulate the protein function. © 2015 American Institute of Chemical Engineers Biotechnol. Prog., 31:615–629, 2015
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Production of recombinant protein therapeutics in cultivated mammalian cells
Wurm, F. M. (2004) · Nature Biotechnology · doi:10.1038/nbt1026 · Cited by 2,032
Nutrition Needs of Mammalian Cells in Tissue Culture
Eagle, H. (1955) · Science · doi:10.1126/science.122.3168.501 · Cited by 1,619
Glycosylation as a strategy to improve antibody-based therapeutics
Jefferis, R. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2804 · Cited by 829 · cited 1×
“A large number of reports describe various impacts of glycosylation on the quality attributes of biologics including in vivo efficacy, PK,(9) ADCC(45,47) and complement-dependent cytotoxicity (CDC) activities,(48) stability and overall structure of the molecule,(45) clearance and half-life in vivo(8) as well as immuno…”
BackgroundCell culture processes for monoclonal antibody production
Li, F., Vijayasankaran, N., Shen, A. (., Kiss, R., & Amanullah, A. (2010) · mAbs · doi:10.4161/mabs.2.5.12720 · Cited by 739
Effects of Charge on Antibody Tissue Distribution and Pharmacokinetics
Boswell, C. A., Tesar, D. B., Mukhyala, K., Theil, F.-P., Fielder, P. J., & Khawli, L. A. (2010) · Bioconjugate Chemistry · doi:10.1021/bc100261d · Cited by 398
Eon‐Duval, A., Broly, H., & Gleixner, R. (2012) · Biotechnology Progress · doi:10.1002/btpr.1548 · Cited by 234 · cited 7×
“In contrast to human IgG, sialic acids are attached to the terminal galactose residues of antibodies expressed in CHO cells via an a-2,3 linkage exclusively.(50) It was reported that by reducing glutamine con-”
BackgroundInfluentialSelf-citationModulation of antibody galactosylation through feeding of uridine, manganese chloride, and galactose
Gramer, M. J., Eckblad, J. J., Donahue, R., Brown, J., Shultz, C., Vickerman, K., Priem, P., van den Bremer, E. T. J., Gerritsen, J., & van Berkel, P. H. C. (2011) · Biotechnology and Bioengineering · doi:10.1002/bit.23075 · Cited by 193
Metabolic control of recombinant protein N‐glycan processing in NS0 and CHO cells
Baker, K. N., Rendall, M. H., Hills, A. E., Hoare, M., Freedman, R. B., & James, D. C. (2001) · Biotechnology and Bioengineering · doi:10.1002/bit.1051 · Cited by 184 · cited 1×
“While improved sialylation of IFN-c was the result of medium supplementation with the specific sialic acid precursor N-acetylmannosamine (ManNAc) at 20 mM in a CHO cell line (cotransfected with genes for dihydrofolate reductase),(109) it remained unchanged for human tissue inhibitor of metalloproteinases 1 (TIMP-1) at…”
Enhanced Production of Monomeric Interferon-β by CHO Cells through the Control of Culture Conditions
Rodriguez, J., Spearman, M., Huzel, N., & Butler, M. (2008) · Biotechnology Progress · doi:10.1021/bp049807b · Cited by 145 · cited 3×
“Other compounds, such as DMSO (18%, v/v) and glycerol (1-2%, v/v) exhibited protein stabilization capabilities.(114,144) In contrast, the addition of copper into the cell culture medium could slightly increase aggregation, whereas a supplementation of the culture medium with cysteine known for to its mild reducing cha…”
BackgroundMetabolic control of recombinant monoclonal antibody N‐glycosylation in GS‐NS0 cells
Hills, A. E., Patel, A., Boyd, P., & James, D. C. (2001) · Biotechnology and Bioengineering · doi:10.1002/bit.10022 · Cited by 127 · cited 1×
“In the absence of synergy, the impact of the galactose concentration on increased galactosylation is limited.(99) The asparagine concentration influenced the distribution of G0F, G1F and G2F, likely due to altered enzyme activity caused by increased intracellular pH, where higher G0F and lower G1F and G2F emerged with…”
Background
Cited by
Perfusion mammalian cell culture for recombinant protein manufacturing – A critical review
Bielser, J.-M., Wolf, M., Souquet, J., Broly, H., & Morbidelli, M. (2018) · Biotechnology Advances · doi:10.1016/j.biotechadv.2018.04.011 · Cited by 263
Self-citationKarst, D. J., Serra, E., Villiger, T. K., Soos, M., & Morbidelli, M. (2016) · Biochemical Engineering Journal · doi:10.1016/j.bej.2016.02.003 · Cited by 151
Media formulation optimization: current and future opportunities
Galbraith, S. C., Bhatia, H., Liu, H., & Yoon, S. (2018) · Current Opinion in Chemical Engineering · doi:10.1016/j.coche.2018.08.004 · Cited by 70
Scale‐Down Model Development in ambr systems: An Industrial Perspective
Sandner, V., Pybus, L. P., McCreath, G., & Glassey, J. (2019) · Biotechnology Journal · doi:10.1002/biot.201700766 · Cited by 63
A two-step procedure for the design of perfusion bioreactors
Wolf, M. K. F., Pechlaner, A., Lorenz, V., Karst, D. J., Souquet, J., Broly, H., & Morbidelli, M. (2019) · Biochemical Engineering Journal · doi:10.1016/j.bej.2019.107295 · Cited by 32
Self-citation
Metadata
- Authors
- Brühlmann, D., Jordan, M., Hemberger, J., Sauer, M., Stettler, M., & Broly, H.
- Venue
- Biotechnology Progress
- Publisher
- Wiley
- Published
- 2015-04-29
- Volume
- 31
- Issue
- 3
- Pages
- 615-629
- ISSN
- 1520-6033 (ISSN-L)
- 8756-7938
- OpenAlex
- W1636483053
- Cited by
- 71
- References
- 12
- FWCI
- 4.12
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.